AMRZ three-lens brief
Evidence-based stock research on AMRZ. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 3% of its 52-week range — deep in the lower band.
- Trading at 3% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- RSI at 30 — technically oversold.
- Underperforming SPY by 22.1pp over 30 days.
- Analyst mean target $56.10 — 39% above current (20 analysts).
AMRZ closed at $40.44 (-1.29%) as of 2026-09-11. Market cap: $22.12B. P/E (trailing) 18.4. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $56.10 — 39% above current (20 analysts).. Concerns: trading at 3% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $3.49B, net income $478.00M, free cash flow $1.13B.
Why three lenses on AMRZ, not one.
A single reasoning model has blind spots it doesn’t know about. We examine AMRZacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/AMRZ" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath AMRZ brief"></iframe>